Cantargia AB (publ)

OM:CANTA Stock Report

Market Cap: SEK 309.0m

Cantargia Valuation

Is CANTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CANTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CANTA?

Key metric: As CANTA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CANTA. This is calculated by dividing CANTA's market cap by their current book value.
What is CANTA's PB Ratio?
PB Ratio6.3x
BookSEK 48.94m
Market CapSEK 308.96m

Price to Book Ratio vs Peers

How does CANTA's PB Ratio compare to its peers?

The above table shows the PB ratio for CANTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.6x
CURAS Curasight
15.5xn/aDKK 206.0m
ALZ Alzinova
2.3x-39.4%SEK 294.2m
LIPUM Lipum
6x-22.2%SEK 286.4m
ACE Ascelia Pharma
2.6x47.2%SEK 284.5m
CANTA Cantargia
6.3x-3.4%SEK 309.0m

Price-To-Book vs Peers: CANTA is good value based on its Price-To-Book Ratio (6.3x) compared to the peer average (6.6x).

Price to Book Ratio vs Industry

How does CANTA's PB Ratio compare vs other companies in the SE Biotechs Industry?

10 CompaniesPrice / BookEstimated GrowthMarket Cap
IVACC Intervacc
0.4x26.6%US$6.62m
COMBI CombiGene
0.5xn/aUS$4.17m
QUIA Quia Pharma
0.5xn/aUS$1.45m
SCOL Scandion Oncology
0.4x69.7%US$1.44m
CANTA 6.3xIndustry Avg. 2.6xNo. of Companies10PB02.44.87.29.612+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CANTA is expensive based on its Price-To-Book Ratio (6.3x) compared to the Swedish Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is CANTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CANTA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CANTA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CANTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 1.68
SEK 8.33
+395.4%
28.3%SEK 10.00SEK 5.00n/a3
Dec ’25SEK 1.80
SEK 8.33
+363.7%
28.3%SEK 10.00SEK 5.00n/a3
Nov ’25SEK 3.06
SEK 12.33
+303.1%
13.8%SEK 14.00SEK 10.00n/a3
Oct ’25SEK 3.13
SEK 12.33
+294.0%
13.8%SEK 14.00SEK 10.00n/a3
Sep ’25SEK 3.99
SEK 12.67
+217.8%
16.2%SEK 15.00SEK 10.00n/a3
Aug ’25SEK 3.61
SEK 12.67
+251.3%
16.2%SEK 15.00SEK 10.00n/a3
Jul ’25SEK 4.41
SEK 12.67
+187.4%
16.2%SEK 15.00SEK 10.00n/a3
Jun ’25SEK 4.80
SEK 12.67
+163.9%
16.2%SEK 15.00SEK 10.00n/a3
May ’25SEK 3.34
SEK 12.67
+279.7%
16.2%SEK 15.00SEK 10.00n/a3
Apr ’25SEK 3.49
SEK 12.67
+262.9%
16.2%SEK 15.00SEK 10.00n/a3
Mar ’25SEK 2.72
SEK 12.67
+365.7%
16.2%SEK 15.00SEK 10.00n/a3
Feb ’25SEK 3.47
SEK 13.67
+294.1%
24.1%SEK 18.00SEK 10.00n/a3
Jan ’25SEK 3.74
SEK 13.67
+265.6%
24.1%SEK 18.00SEK 10.00SEK 1.693
Dec ’24SEK 3.54
SEK 13.67
+286.5%
24.1%SEK 18.00SEK 10.00SEK 1.803
Nov ’24SEK 3.43
SEK 14.00
+308.4%
26.7%SEK 19.00SEK 10.00SEK 3.063
Oct ’24SEK 4.26
SEK 14.00
+228.6%
26.7%SEK 19.00SEK 10.00SEK 3.133
Sep ’24SEK 4.12
SEK 14.00
+240.0%
26.7%SEK 19.00SEK 10.00SEK 3.993
Aug ’24SEK 5.05
SEK 17.00
+236.6%
30.8%SEK 26.00SEK 13.00SEK 3.614
Jul ’24SEK 4.08
SEK 17.00
+316.7%
30.8%SEK 26.00SEK 13.00SEK 4.414
Jun ’24SEK 4.68
SEK 17.00
+262.9%
30.8%SEK 26.00SEK 13.00SEK 4.804
May ’24SEK 6.09
SEK 17.00
+179.1%
30.8%SEK 26.00SEK 13.00SEK 3.344
Apr ’24SEK 6.78
SEK 17.67
+160.8%
33.4%SEK 26.00SEK 13.00SEK 3.493
Mar ’24SEK 7.82
SEK 20.00
+155.8%
24.5%SEK 26.00SEK 14.00SEK 2.723
Feb ’24SEK 6.08
SEK 22.00
+261.8%
9.1%SEK 24.00SEK 20.00SEK 3.472
Jan ’24SEK 3.08
SEK 22.00
+614.3%
9.1%SEK 24.00SEK 20.00SEK 3.742

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:21
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cantargia AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Soo RomanoffEdison Investment Research
null nullLife Sciences Research International BV